Nxera Pharma announced a net profit of JPY 1,591 million (US$10.1 million) for Q2 2026, reversing a prior loss due to multiple milestone payments from partners like Neurocrine, AbbVie, and Lilly. The company progressed regulatory approvals and commercial launches in Asia for drugs treating insomnia and Duchenne Muscular Dystrophy, including key designations in South Korea and Taiwan market entry plans. Nxera also advanced its proprietary pipeline and collaborations, notably benefiting from Lilly's acquisition of Centessa Pharmaceuticals, which co-developed orexin receptor agonists with Nxera. With strong revenue growth and reduced R&D and SG&A expenses, Nxera is positioned for continued growth and value creation in the second half of 2026.
Eli Lilly will present mid-stage trial results for eloraTZP, a two-drug obesity treatment, on September 30. The data will show if the combo offers significantly better weight loss and tolerability than tirzepatide alone, crucial for sustaining the co...
The FDA has granted full approval to Eli Lilly's Inluriyo (imlunestrant) combined with Verzenio (abemaciclib) for treating adults with estrogen receptor-positive (ER+), HER2-negative, ESR1-mutated advanced or metastatic breast cancer after progressio...
